RANI
NASDAQ · Pharmaceuticals
Rani Therapeutics Holdings-A
$0.86
+0.01 (+1.22%)
Financial Highlights (FY 2026)
Revenue
3.35M
Net Income
-60,872,678
Gross Margin
—
Profit Margin
-1,817.1%
Rev Growth
-15.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 42.7% | 42.7% |
| Operating Margin | -2,381.3% | -2,143.1% | 20.3% | 21.7% |
| Profit Margin | -1,817.1% | -1,726.2% | 16.4% | 15.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.35M | 3.97M | 51.04M | 44.44M |
| Gross Profit | — | — | 21.81M | 18.99M |
| Operating Income | -79,793,974 | -85,128,706 | 10.38M | 9.66M |
| Net Income | -60,872,678 | -64,942,401 | 8.38M | 6.94M |
| Gross Margin | — | — | 42.7% | 42.7% |
| Operating Margin | -2,381.3% | -2,143.1% | 20.3% | 21.7% |
| Profit Margin | -1,817.1% | -1,726.2% | 16.4% | 15.6% |
| Rev Growth | -15.6% | -15.6% | +13.5% | +18.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 49.86M | 51.71M |
| Total Equity | — | — | 50.59M | 54.70M |
| D/E Ratio | — | — | 0.99 | 0.95 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -77,912,144 | -87,738,900 | 12.88M | 11.35M |
| Free Cash Flow | — | — | 6.14M | 6.76M |